PT - JOURNAL ARTICLE AU - Nsreen Ragab AU - Yasser Abdelhafez AU - Waleed Diab AU - Wael Abd-El-Ghani AU - Mohammed Mekkawy TI - <strong>Technetium-99m pentavalent dimercaptosuccinic acid (<sup>99m</sup>Tc-DMSA-V) brain SPECT/CT and Karnofsky performance score predict survival in patients with glioma</strong> DP - 2017 May 01 TA - Journal of Nuclear Medicine PG - 1284--1284 VI - 58 IP - supplement 1 4099 - http://jnm.snmjournals.org/content/58/supplement_1/1284.short 4100 - http://jnm.snmjournals.org/content/58/supplement_1/1284.full SO - J Nucl Med2017 May 01; 58 AB - 1284Objectives: To evaluate the prognostic role of post-therapy 99mTc-DMSA-V brain SPECT/CT scans in patients with glioma.Methods: Patients with glioma underwent post-treatment SPECT/CT scanning using 99mTc-DMSA-V in this prospective study. Scan results were reported as positive or negative for tumor residual/recurrence. Three -year overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow-up.Results: A total of 37 patients were eligible for analysis with mean survival of 37.5 months (range = 28.6 – 46.5). At the end of follow-up, 13 patients died (3-year OS = 42%). Ten out of 17 patients with positive DMSA-V scan findings died compared to 3 out of 20 patients with negative scans. Three-year OS were 13% for the positive group with mean survival of 22.2 months compared to 74% and mean survival of 50.3 months for the negative group (P = 0.003). Additionally, patients with negative scans survived significantly longer than positive group after their date of scanning (mean survival 20.7 months vs. 11.0 months; P = 0.001). DMSA-V scan results were still significant predictor of OS after adjusting for age, gender and pathology in Cox proportional hazard model (P = 0.03; Hazards ratio [HR] = 4.8 [95% CI = 1.2 – 19.7]). However, DMSA-V scan results were strongly associated with Karnofsky performance scale (KPS) (P = 0.002). A scoring system which includes both DMSA-V scan results and KPS (cut-off 80) identified 3 different groups with significant difference in OS; score 0 = negative scan &amp; KPS 蠅 80 (reference group), score 1 = positive scan or KPS &lt; 80 and score 2 = positive scan with KPS &lt; 80 (P = 0.006). Patients with score 2 have HR of 11.4 compared to 3.8 for score 1.Conclusion: Post-therapy SPECT/CT scanning with 99mTc-DMSA-V in patients with glioma is a potential prognostic factor for OS and may be helpful in risk stratification of glioma patients after their treatment. Supporting graph: Supporting TablesView this table: